创新药驶向“新航海时代”

Core Insights - The article discusses the successful international pricing strategy of Chinese innovative drug Yili Shu, which is priced at approximately $4,600 in the U.S. compared to its domestic price of 2,388 yuan, indicating a shift in the global valuation of Chinese innovative drugs [3][4][5] - The recognition of the value of Chinese innovative drugs in the global market is attracting multinational pharmaceutical companies to engage more deeply in the development of this industry [3][4] Group 1: Pricing and Market Strategy - Yili Shu's pricing in the U.S. reflects its integration into the global mainstream market value pricing system, moving beyond cost-based pricing [3][4] - The core of product pricing in the U.S. is based on clinical value, safety, and convenience rather than domestic costs, leading to significant price differences across markets [5] - The essence of premium pricing lies in the product's replicability and sustainability in supply and usage, rather than a one-time high price [5][6] Group 2: International Collaboration and Growth - By 2025, the total amount of foreign licensing for Chinese innovative drugs is expected to reach a historical high, with a shift from single product licensing to joint research and development [3][8] - The partnership between Heng Rui Pharmaceutical and GSK, involving a potential total amount of $12 billion, highlights the growing recognition of the global competitiveness of Chinese innovative drugs [8] - The NewCo model is emerging as a new path for Chinese innovative drug companies to enter international markets, allowing for better decision-making and sharing of long-term benefits [8][9] Group 3: Challenges and Future Directions - The Chinese innovative drug industry is transitioning from merely entering the U.S. and European markets to establishing a sustainable competitive presence [9][10] - Key challenges include developing a comprehensive intellectual property defense system, ensuring long-term compliance efficiently, and understanding cultural and commercial differences in the global market [9][10] - Future trends indicate a shift from selling products to exporting technological capabilities, with a focus on joint development and early involvement in global research decisions [10]